Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NAR-001
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : NanoRetinal
Deal Size : Undisclosed
Deal Type : Partnership
GBI Partners with NanoRetinal to Advance Vision-Restoring Therapy for Retinal Diseases
Details : The partnership to develop and manufacture NAR-001, NanoRetinal's proprietary nanoparticle technology designed to restore and/or preserve vision in patients with Inherited Retinal Diseases (IRD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 09, 2025
Lead Product(s) : NAR-001
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : NanoRetinal
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : 4A10
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Allterum Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
GBI Biomanufacturing And Allterum Collaborate on Therapeutic Antibody Trials
Details : The collaboration aims to advance Allterum's lead candidate 4A10, a monoclonal antibody (mAb) targeting CD127, a receptor expressed by a broad variety of cancers, into clinic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : 4A10
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Allterum Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration